FOXO4-DRI

FOXO4-DRI is an experimental cell-penetrating peptide investigated in preclinical models involving the FOXO4–p53 interaction and cellular senescence. Published evidence remains limited primarily to cellular and animal models, and no established human safety or efficacy profile exists.

The D-retro-inverso peptide is intended to interfere with FOXO4-mediated retention of p53 in senescent cells, promoting p53 relocation and apoptosis in selected experimental models.

Early preclinical evidence.

Level V, Early mechanistic research

There is no established human efficacy, dosing, pharmacokinetic, or safety framework. Senescent-cell heterogeneity and tissue-specific effects complicate translation.

Potential risks include unintended apoptosis, tissue injury, immune effects, and unpredictable consequences of altering p53-related signaling.

Investigational research peptide; no FDA-approved drug product.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

• FOXO4-DRI, 10 mgLyophilized

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.